Attention Turns To Celgene's Other Pipeline Prospects Following Second Positive Luspatercept Read-Out
Executive Summary
Celgene and Acceleron's novel erythroid maturation agent, luspatercept, has reported positive Phase III results in a second potential indication, beta-thalassemia, and approval filings are confirmed for the first half of 2019.
You may also be interested in...
Key Drug Launches To Plan For In 2019
Around three dozen key late-stage products could reach their first markets in 2019, according to a recent report from Informa Pharma's Biomedtracker. Company execs may need to plan for the disruptive potential of this group of new medicines on established markets and standards of care.
Celgene Maintains Otezla Confidence, But Is Reconsidering IBD Indications
Second quarter Otezla sales came in slightly lower than consensus, but Celgene believes changes in inventory levels will smooth out for the remainder of 2018. However, the company is reconsidering its pursuit of IBD indications for Otezla in deference to its potential blockbuster ozanimod.
Pharma Q2 Results Preview: Celgene, Amgen, Allergan And AbbVie
With the FDA updating its stance on interchangeability, analysts will be pushing Amgen and AbbVie on how the policy changes will affect biosimilar competition. Celgene and Allergan will be under pressure for R&D updates; Allergan remains in the hot seat on its pipeline growth strategy from activist investors.